Telix Pharmaceuticals Ltd
ASX:TLX

Watchlist Manager
Telix Pharmaceuticals Ltd Logo
Telix Pharmaceuticals Ltd
ASX:TLX
Watchlist
Price: 14.59 AUD -0.14% Market Closed
Market Cap: 4.9B AUD

Telix Pharmaceuticals Ltd
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Telix Pharmaceuticals Ltd
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Telix Pharmaceuticals Ltd
ASX:TLX
Stock-Based Compensation
AU$13m
CAGR 3-Years
58%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Opthea Ltd
ASX:OPT
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mesoblast Ltd
ASX:MSB
Stock-Based Compensation
$22.1m
CAGR 3-Years
59%
CAGR 5-Years
24%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Stock-Based Compensation
$149m
CAGR 3-Years
8%
CAGR 5-Years
15%
CAGR 10-Years
38%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Stock-Based Compensation
AU$2m
CAGR 3-Years
-31%
CAGR 5-Years
4%
CAGR 10-Years
-10%
PYC Therapeutics Ltd
ASX:PYC
Stock-Based Compensation
AU$974k
CAGR 3-Years
17%
CAGR 5-Years
6%
CAGR 10-Years
15%
No Stocks Found

Telix Pharmaceuticals Ltd
Glance View

Telix Pharmaceuticals Ltd. is an innovative biopharmaceutical company that has carved a niche for itself in the realm of targeted radiation therapy and imaging, primarily focusing on cancer treatment. Established with the vision of transforming the landscape of oncology, Telix develops molecularly-targeted radiation (MTR) products aimed at diagnosing and treating a range of significant unmet medical needs. The company's lead product, Illuccix, gained significant attention after securing regulatory approvals for use in imaging prostate cancer. Through strategic alliances with academic and research institutions, as well as commercial entities, Telix harnesses the power of radioisotopes to create compounds that bind to specific cancer cells, allowing for both precise imaging and treatment of malignancies. The business model of Telix hinges on a blend of research and development, regulatory acumen, and strategic commercialization. By advancing a pipeline of diagnostic and therapeutic radiopharmaceuticals, Telix aims to address the full cycle of cancer care—from early detection to personalized treatment. Revenue is primarily generated through the sale of its approved products, alongside potential milestone payments and royalties from partnerships. The commercial success of Illuccix and other pipeline candidates underscores the company's ability to effectively translate scientific research into marketable therapies, positioning Telix as a formidable player in the competitive arena of cancer diagnosis and treatment. By continuing to expand its portfolio and push the boundaries of nuclear medicine, Telix seeks to deliver life-changing therapies while driving sustainable growth.

TLX Intrinsic Value
HIDDEN
Show

See Also

What is Telix Pharmaceuticals Ltd's Stock-Based Compensation?
Stock-Based Compensation
13m AUD

Based on the financial report for Dec 31, 2024, Telix Pharmaceuticals Ltd's Stock-Based Compensation amounts to 13m AUD.

What is Telix Pharmaceuticals Ltd's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
49%

Over the last year, the Stock-Based Compensation growth was 122%. The average annual Stock-Based Compensation growth rates for Telix Pharmaceuticals Ltd have been 58% over the past three years , 49% over the past five years .

Back to Top